HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Nefazodone in social phobia.

AbstractBACKGROUND:
A variety of drug treatments have been shown to be effective in the treatment of social phobia. This study attempted to assess the efficacy of nefazodone, a new novel serotonergic drug, in the treatment of social phobia.
METHOD:
Nefazodone was administered to 23 patients who had a primary DSM-IV diagnosis of social phobia, generalized type (diagnosed by the Structured Clinical Interview for DSM-IV), in a 12-week open clinical trial. Treatment began at 100 mg of nefazodone daily and was increased according to clinical response and side effects. Patients completed self-report measures at baseline and at weeks 4, 8, and 12. These measures included the Fear of Negative Evaluation scale, the Social Avoidance and Distress scale, the Social Anxiety Thoughts Questionnaire, the Fear Questionnaire, the State-Trait Anxiety Inventory, the Beck Depression Inventory, the Social Adjustment Scale Self-Report, and the Sheehan Disability Scale. Clinicians completed the Liebowitz Panic and Social Phobic Disorders rating form and the Brief Social Phobia Scale.
RESULTS:
Twenty-one of the 23 patients completed the 12-week trial. Sixteen (69.6%) were considered responders (moderate or marked improvement), and 7 (30.4%) were considered to be nonresponders (minimal improvement or no change in symptoms). Measures of social anxiety, social phobic avoidance, depression, and social functioning showed a statistically significant change at endpoint.
CONCLUSION:
These findings support a role for nefazodone in the treatment of social phobia, generalized type. Controlled studies will be required to further investigate this preliminary finding as well as to compare nefazodone with other pharmacologic treatments of social phobia.
AuthorsM Van Ameringen, C Mancini, J M Oakman
JournalThe Journal of clinical psychiatry (J Clin Psychiatry) Vol. 60 Issue 2 Pg. 96-100 (Feb 1999) ISSN: 0160-6689 [Print] UNITED STATES
PMID10084635 (Publication Type: Case Reports, Clinical Trial, Journal Article)
Chemical References
  • Antidepressive Agents, Second-Generation
  • Serotonin Agents
  • Triazoles
  • nefazodone
Topics
  • Adult
  • Antidepressive Agents, Second-Generation (administration & dosage, therapeutic use)
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Phobic Disorders (diagnosis, drug therapy, psychology)
  • Psychiatric Status Rating Scales
  • Serotonin Agents (administration & dosage, therapeutic use)
  • Treatment Outcome
  • Triazoles (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: